Cargando…
Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort
BACKGROUND: With the introduction of DNA-damaging therapies into standard of care cancer treatment, there is a growing need for predictive diagnostics assessing homologous recombination deficiency (HRD) status across tumor types. Following the strong clinical evidence for the utility of DNA-sequenci...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148513/ https://www.ncbi.nlm.nih.gov/pubmed/35643464 http://dx.doi.org/10.1186/s12885-022-09669-z |
_version_ | 1784717049728073728 |
---|---|
author | Leibowitz, Benjamin D. Dougherty, Bonnie V. Bell, Joshua S. K. Kapilivsky, Joshuah Michuda, Jackson Sedgewick, Andrew J. Munson, Wesley A. Chandra, Tushar A. Dry, Jonathan R. Beaubier, Nike Igartua, Catherine Taxter, Timothy |
author_facet | Leibowitz, Benjamin D. Dougherty, Bonnie V. Bell, Joshua S. K. Kapilivsky, Joshuah Michuda, Jackson Sedgewick, Andrew J. Munson, Wesley A. Chandra, Tushar A. Dry, Jonathan R. Beaubier, Nike Igartua, Catherine Taxter, Timothy |
author_sort | Leibowitz, Benjamin D. |
collection | PubMed |
description | BACKGROUND: With the introduction of DNA-damaging therapies into standard of care cancer treatment, there is a growing need for predictive diagnostics assessing homologous recombination deficiency (HRD) status across tumor types. Following the strong clinical evidence for the utility of DNA-sequencing-based HRD testing in ovarian cancer, and growing evidence in breast cancer, we present analytical validation of the Tempus HRD-DNA test. We further developed, validated, and explored the Tempus HRD-RNA model, which uses gene expression data from 16,750 RNA-seq samples to predict HRD status from formalin-fixed paraffin-embedded tumor samples across numerous cancer types. METHODS: Genomic and transcriptomic profiling was performed using next-generation sequencing from Tempus xT, Tempus xO, Tempus xE, Tempus RS, and Tempus RS.v2 assays on 48,843 samples. Samples were labeled based on their BRCA1, BRCA2 and selected Homologous Recombination Repair pathway gene (CDK12, PALB2, RAD51B, RAD51C, RAD51D) mutational status to train and validate HRD-DNA, a genome-wide loss-of-heterozygosity biomarker, and HRD-RNA, a logistic regression model trained on gene expression. RESULTS: In a sample of 2058 breast and 1216 ovarian tumors, BRCA status was predicted by HRD-DNA with F1-scores of 0.98 and 0.96, respectively. Across an independent set of 1363 samples across solid tumor types, the HRD-RNA model was predictive of BRCA status in prostate, pancreatic, and non-small cell lung cancer, with F1-scores of 0.88, 0.69, and 0.62, respectively. CONCLUSIONS: We predict HRD-positive patients across many cancer types and believe both HRD models may generalize to other mechanisms of HRD outside of BRCA loss. HRD-RNA complements DNA-based HRD detection methods, especially for indications with low prevalence of BRCA alterations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09669-z. |
format | Online Article Text |
id | pubmed-9148513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91485132022-05-30 Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort Leibowitz, Benjamin D. Dougherty, Bonnie V. Bell, Joshua S. K. Kapilivsky, Joshuah Michuda, Jackson Sedgewick, Andrew J. Munson, Wesley A. Chandra, Tushar A. Dry, Jonathan R. Beaubier, Nike Igartua, Catherine Taxter, Timothy BMC Cancer Research BACKGROUND: With the introduction of DNA-damaging therapies into standard of care cancer treatment, there is a growing need for predictive diagnostics assessing homologous recombination deficiency (HRD) status across tumor types. Following the strong clinical evidence for the utility of DNA-sequencing-based HRD testing in ovarian cancer, and growing evidence in breast cancer, we present analytical validation of the Tempus HRD-DNA test. We further developed, validated, and explored the Tempus HRD-RNA model, which uses gene expression data from 16,750 RNA-seq samples to predict HRD status from formalin-fixed paraffin-embedded tumor samples across numerous cancer types. METHODS: Genomic and transcriptomic profiling was performed using next-generation sequencing from Tempus xT, Tempus xO, Tempus xE, Tempus RS, and Tempus RS.v2 assays on 48,843 samples. Samples were labeled based on their BRCA1, BRCA2 and selected Homologous Recombination Repair pathway gene (CDK12, PALB2, RAD51B, RAD51C, RAD51D) mutational status to train and validate HRD-DNA, a genome-wide loss-of-heterozygosity biomarker, and HRD-RNA, a logistic regression model trained on gene expression. RESULTS: In a sample of 2058 breast and 1216 ovarian tumors, BRCA status was predicted by HRD-DNA with F1-scores of 0.98 and 0.96, respectively. Across an independent set of 1363 samples across solid tumor types, the HRD-RNA model was predictive of BRCA status in prostate, pancreatic, and non-small cell lung cancer, with F1-scores of 0.88, 0.69, and 0.62, respectively. CONCLUSIONS: We predict HRD-positive patients across many cancer types and believe both HRD models may generalize to other mechanisms of HRD outside of BRCA loss. HRD-RNA complements DNA-based HRD detection methods, especially for indications with low prevalence of BRCA alterations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09669-z. BioMed Central 2022-05-28 /pmc/articles/PMC9148513/ /pubmed/35643464 http://dx.doi.org/10.1186/s12885-022-09669-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Leibowitz, Benjamin D. Dougherty, Bonnie V. Bell, Joshua S. K. Kapilivsky, Joshuah Michuda, Jackson Sedgewick, Andrew J. Munson, Wesley A. Chandra, Tushar A. Dry, Jonathan R. Beaubier, Nike Igartua, Catherine Taxter, Timothy Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort |
title | Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort |
title_full | Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort |
title_fullStr | Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort |
title_full_unstemmed | Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort |
title_short | Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort |
title_sort | validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148513/ https://www.ncbi.nlm.nih.gov/pubmed/35643464 http://dx.doi.org/10.1186/s12885-022-09669-z |
work_keys_str_mv | AT leibowitzbenjamind validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT doughertybonniev validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT belljoshuask validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT kapilivskyjoshuah validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT michudajackson validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT sedgewickandrewj validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT munsonwesleya validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT chandratushara validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT dryjonathanr validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT beaubiernike validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT igartuacatherine validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort AT taxtertimothy validationofgenomicandtranscriptomicmodelsofhomologousrecombinationdeficiencyinarealworldpancancercohort |